{"schema_version":"secwatch.filing_event.v1","accession":"0001161697-26-000027","form_type":"8-K","ticker":"KRMD","cik":"0000704440","company_name":"KORU Medical Systems, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.496828+00:00","generated_at":"2026-05-16T10:59:03.372346+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"KORU Medical prelim Q4 revenue $10.9M (+23% YoY); FY revenue $41.1M (+22% YoY); positive op cash flow","bullets":["Preliminary Q4 2025 net revenue $10.9M, up 23% YoY; full year net revenue $41.1M, up 22% YoY.","Ending cash balance $8.9M; positive cash flow from operations in Q4 and for full year.","Submitted 510(k) for Freedom Infusion System for use with Phesgo, expanding into oncology.","Company plans to release final 2025 results and 2026 guidance in early March 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001161697-26-000027","json":"https://secwatch.observer/filing/0001161697-26-000027.json","markdown":"https://secwatch.observer/filing/0001161697-26-000027.md","text":"https://secwatch.observer/filing/0001161697-26-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/704440/000116169726000027/0001161697-26-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/704440/000116169726000027/form_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:59:03.372346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}